FDA approves Mercado-heavy immunotherapy Keytruda (pembrolizumab) to treat patients with advanced cervical cancer

recently, the(MSD) of Theof Mersadon announced that the U.SFDAapprove its heavy immunotherapy, The Keytruda, to treat patients with advanced cervical cancerKeytrudaKeytruda is a monoclonal antibody that binds to pD-1 receptors, blocks its interaction with PD-L1 and PD-L2, and suppresses tumors through PD-1 pathway-mediated immune responses, including anti-tumor immune responsesIn tumor models in mice with the same genotype, Keytruda blocks PD-1 activity and slows tumor growthbefore that, Keytruda had been approved for cancer treatment for melanoma, non-small cell lung cancer, classic Hodgkin's lymphoma, head and neck squamous, and urinary skin cancerstudiesthe effectiveness of Keytruda in cervical cancer has been demonstrated in a clinicaltrialcalled KEYNOTE-158KEYNOTE-158 II Is a global, open, non-random, multilinear, multicenter clinical study with objective remission (ORR), which recruited 98 patients with recurrent or metastatic cervical cancer and received Keytruda (200mg) treatment every three weeksin 77 (79%) patients who expressed PD-L1 (no less than 1 overall positive score), Keytruda achieved an overall remission rate of 14.3% (95% CI: 7.4% - 24.1%), with a full remission rate of 2.6%In patients whose treatment took effect, the median remission time had not yet been reached, and 91% of patients had more than half a year of remission timeKeytruda did not show results in patients with a tumor PD-L1 expression of less than 1 based on this data, the FDA approved its listing to treat patients with advanced cervical cancer that is still developing after chemotherapy and expressed PD-L1